Merck & Co., Inc. is 228.3x more valuable than MoonLake Immunotherapeutics by market capitalization ($298.26 B vs $1.31 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | MLTX | MRK |
|---|---|---|
| Market cap | $1.31 B | $298.26 B |
| US-listed rank | #2448 | #45 |
| Revenue (latest FY) | - | $65.01B |
| Net income (latest FY) | -$227.32M | $18.25B |
| Net margin | - | 28.1% |
| P/E (trailing FY) | - | 16.3 |
| SEC filings | 296 | 996 |
Merck & Co., Inc. is 228.3x more valuable than MoonLake Immunotherapeutics by market capitalization ($298.26 B vs $1.31 B).
Full pages: MoonLake Immunotherapeutics and Merck & Co., Inc., or browse the full rankings.